Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 6, 2000, Pages 1433-1436

  Fassett, Michael J ^a   Bohn, Yvonne C ^b   Kuo, John ^b   Wing, Deborah A ^b  

^a WOMEN S AND CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

Activated protein C resistance; Factor V Leiden; Pregnancy

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; FEMALE; GENE MUTATION; GENETIC RESISTANCE; GESTATIONAL AGE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OLIGOHYDRAMNIOS; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SPAIN;

EID: 0033920773     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.106134     Document Type: Conference Paper

References (17)

1. 1. Centers for Disease Control and Prevention. Maternal mortality - United States, 1982-1996. JAMA 1998;280:1042-3.
2. 2. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
3. 3. Herrmann FH, Koesling M, Schroder W, Altman R, Jiménez Bonilla R, Lopaciuk S, et al. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 1997;14:403-11.
4. 4. Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet 1997;73:334-6.
5. 5. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venons thromboembolism screening. JAMA 1997; 277:1305-7.
6. 6. US Census Bureau. American fact finder [publication online] [cited 1999 May 23]. Available from: URL:http://factfinder.census.gov/.
7. 7. Axelsson F, Rosén S. APC resistance product monograph 1997. Version 2.1. Mölndal (Sweden): Chromogenix AB; 1997. p. 13.
8. 8. Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost 1995;74:874-8.
9. 9. Liebman HA, Sutherland D, Bacon R, McGehee W. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance. Br J Haematol 1996;95:550-3.
10. 10. Kupfermine MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13.
11. 11. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97:551-4.
12. 12. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997;176:457-60.
13. 13. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-5.
14. 14. Brenner B, Lanir N, Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996;92:999-1001.
15. 15. Mathonnet F, de Mazancourt P, Bastenaire B, Morot M, Benattar N, Beufé S, et al. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol 1996;92:244-6.
16. 16. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995;90:725-7.
17. 17. Rouse DJ, Goldenberg RL, Wenstrom KD. Antenatal screening for factor V Leiden mutation: a critical appraisal. Obstet Gynecol 1997;90:848-51.